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Abstract
Background
Visceral leishmaniasis (VL) is a life-threatening disease caused by protozoan parasites of
the Leishmania donovani complex. Early case detection followed by adequate treatment is
essential to the control of VL. However, the available diagnostic tests are either invasive
and require considerable expertise (parasitological demonstration of the parasite in tissue
smears) or unable to distinguish between past and active infection (serological methods).
Therefore, we aimed to develop a lateral flow assay in the form of an immunochromato-
graphic test (ICT) device based on the detection of a circulating Leishmania antigen using
monoclonal antibodies (mAbs).
Methodology/Principal Findings
mAbs were produced by fusion of murine myeloma cells with splenocytes isolated from a
mouse immunized with L. donovani soluble crude antigen. Out of 12 cloned hybridoma cell
lines, two secreted mAbs recognizing the same leishmanial protein. These mAbs were
used to produce an ICT as a sandwich assay for the detection of circulating antigen in
serum and blood samples. The ICT was evaluated with 213 serum samples from VL
patients living in VL endemic areas in China, and with 156 serum samples from patients
with other diseases as well as 78 serum samples from healthy donors. Sensitivity, specific-
ity and diagnostic efficiency of the new ICT was 95.8%, 98.7% and 97.3%, respectively.
Compared with a commercially available antibody detecting ICT, our antigen-based ICT
performed slightly better.
Conclusion/Significance
The newly developed ICT is an easy to use and more accurate diagnostic tool which fulfils
the performance and operational characteristics required for VL case detection under field
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and laboratory conditions. As our ICT detects a circulating antigen, it will also be useful in
monitoring treatment success and diagnosing VL in immunocompromised patients.
Author Summary
Visceral leishmaniasis is a neglected disease caused by different species of protozoan para-
sites of the genus Leishmania. The disease is endemic in 61 countries, and in many of
them it poses a serious public health issue. As visceral leishmaniasis is fatal if left
untreated, early diagnosis is essential for treatment and control of the disease. Current
available diagnostic tests are either difficult to carry out under field conditions or insuffi-
ciently accurate. In this study we developed a new diagnostic test which detects a circula-
tion parasite-derived antigen in serum or blood samples of patients with visceral
leishmaniasis. We found that our test performed better than most other tests based on the
detection of parasite-specific antibodies. In addition, as our test is a device for the detec-
tion of an acute infection, it will be useful to validate treatment and in the diagnosis of the
disease in patients with deficient antibody production (as in AIDS patients).
Introduction
Visceral leishmaniasis (VL), or kala-azar, is a vector-borne disease caused by protozoan para-
sites belonging to the Leishmania donovani complex, which includes L. donovani, L. infantum
and L. chagasi. The parasites infect and multiply preferentially in macrophages of the spleen,
liver, bone marrow, and lymph nodes of their mammalian host. VL is a systemic disease and is
fatal if left untreated. The disease is endemic in large areas of the tropics, subtropics and the
Mediterranean Basin affecting 61 countries. It is estimated that approximately 200,000 to
400,000 cases of VL occur annually and that about 20,000 to 40,000 people die each year from
the disease [1]. VL is also an important public health problem in China being endemic in six
provinces or autonomous regions in western China including Xinjiang, Gansu, Sichuan,
Shaanxi, Shanxi and Inner Mongolia [2–4]. The causative agents of VL in China are L. dono-
vani and L. infantum [4]. Since the clinical features of VL mimic several other common dis-
eases, accurate and early diagnosis is crucial for treatment and control of VL as the drugs
currently used for chemotherapy have significant toxic side effects [5, 6].
Parasitological detection remains the gold standard for diagnosis of VL because of its high
specificity [7]. However, as for all microscopic procedures, parasitological VL diagnosis is
affected by variability in detection sensitivity (e.g. the sensitivity of bone marrow smears varies
between 60% to 85% while that of splenic aspirates can exceed 95% [7]) and by the expertise of
the microscopist. In addition, invasive bone marrow and spleen aspiration are painful and
risky techniques. Culturing the parasite can improve the sensitivity of VL diagnosis but can be
affected by contamination of bacteria or yeast species and are time-consuming [7].
Since a strong humoral response is generally induced in VL patients, serodiagnosis is an
alternative to detection of the parasite in tissue samples. Serological tests for diagnosis of VL
(e.g. enzyme-linked immunosorbent assay (ELISA), indirect fluorescence antibody test (IFAT),
direct agglutination test (DAT) and immunochromatographic test (ICT)) are usually based on
unpurified or recombinant antigens and can achieve sensitivities of>90% [8–11]. However,
these tests cannot diagnose relapses as patients remain positive for several months or years
after recovery [12, 13]. In addition, these test are limited in HIV patients co-infected with
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Leishmania where antibody response is very poor [14]. Molecular techniques such as polymer-
ase chain reaction (PCR) assays have improved sensitivity and accuracy compared to parasito-
logical and serological methods in the diagnosis of VL [15–17]. However, molecular
techniques require competent technical personnel, sensitive equipment and continuous elec-
tricity supply, and are considerably more expensive than serological tests. Hence, molecular
diagnostic tests are not suitable for the detection of VL in endemic regions under field
conditions.
The detection of circulating pathogen antigens is an alternative immunodiagnostic test to
identify an infection. This method is usually more specific than the detection of antibodies. In
addition, antigen levels generally correlate with the pathogen load. In contrast to the detection
of antibodies, antigen detection can be used to determine the treatment efficacy and to diag-
nose immunocompromised patients. The detection of circulating antigens can be performed as
a lateral flow assay in the form of an ICT. This technique is a simple, rapid, and reliable method
which can be easily carried out by inexperienced personnel under field condition. In this study
we developed an ICT for the diagnosis of VL using monoclonal antibodies (mAbs) specific to
an antigen of viscerotropic Leishmania species and compared the test with a commercially
available ICT for the detection of anti-L. donovani antibody.
Methods
Ethics statement
This study was reviewed and approved by the Ethics Review Committee of the National Insti-
tute of Parasitic Diseases, Chinese Center for Disease Control and Prevention in Shanghai. All
subjects gave their informed written consent specifying that their serum samples can be used
for future studies. All serum samples were given a unique identification number to ensure that
they were anonymized for any subsequent study.
Animal care and handling was in accordance with the standards specified in the Guidelines
for the Care and Use of Laboratory Animals and approved by the Ethics Committee for Animal
Care and Experimentation (SYXK2011-0127) and international animal experimentation guide-
lines were followed. The study and its protocols were approved by the Ethics Committee of the
National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention.
All surgeries were performed under sodium pentobarbital anesthesia and every effort was
made to minimize the suffering of the animals.
Serum samples
A total of 213 serum samples from VL patients were investigated in this study: 135 serum sam-
ples were kindly provided by the Center for Disease Control and Prevention of Xinjiang Uygur
Autonomous Region of which 64 were from an endemic area of anthroponotic type of VL
(AVL) and 71 from an endemic area of desert sub-type of zoonotic VL (DST-ZVL), and 78
were kindly provided by the Gansu Provincial Center for Disease Control and Prevention
which were from an endemic area of mountain sub-type of zoonotic VL (MST-ZVL). All VL
patients were diagnosed by microscopic examinations of bone marrow smears.
In addition, 156 serum samples from patients with other diseases, including 31 with leprosy,
43 with malaria, 30 with cystic echinococcosis, 25 with schistosomiasis (Schistosoma japoni-
cum), and 27 with toxoplasmosis as well as 78 serum samples from healthy donors were
included as negative controls.
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Parasite culture and antigen preparation
Seven different Leishmania species and strains were used in this study (Table 1). The parasites
were grown as promastigotes in 199 medium at 24°C. Promastigotes were harvested at loga-
rithmic growth phase by centrifugation at 3000 × g for 15 min, washed 3 times with phosphate
buffered saline (PBS) and lysed by re-suspension in approximately equal volume of deionized
water containing 1 mM EDTA, 1 mM ε-aminocaproic acid and 1 mM dithiothreitol for 10
min on ice. Then, the cell suspension was subjected to three freeze-thaw cycles comprising liq-
uid nitrogen to a 37°C warmed-up water bath, followed by three cycles of 1-min sonication.
The lysates were centrifuged at 10000 × g for 30 min at 4°C. The supernatant was recovered
and the protein concentration was determined using DC Protein Assay Kit (Bio-Rad Laborato-
ries). The extract was stored at -20°C until use.
Production of monoclonal antibodies
Eight-week-old female BALB/c mice were immunized intraperitoneally with 50 μg soluble L.
donovaniMHOM/CN/80/XJ801 antigen emulsified in Freund's complete adjuvant. Four and
eight weeks later, the mice received a booster intraperitoneal injection with the same amount
of the antigen emulsified in Freund's incomplete adjuvant. Two weeks after the last injection,
mice were tail-bled and the reactivity of sera was tested for the presence of anti-leishmanial
antibodies by ELISA. Finally, mice were given an injection of 50 μg antigen through the caudal
vein and three days later, the animals were killed and their spleens taken for generation of
hybridomas.
Cell fusion and selection of hybridomas were carried out essentially as described by Köhler
and Milstein [18]. Briefly, spleen lymphocytes from immunized mice were fused with SP2/0
murine myeloma cells at a 5:1 ratio using PEG 1000 (50%) as fusing agent. Hybridomas were
selected and maintained as described by Malavasi et al. [19]. Culture supernatants were
screened for the presence of antibodies by ELISA using promastigote extract as antigen. Anti-
body producing hybridomas were selected and cloned three times by limiting dilution. Ascites
were obtained by injecting hybridomas into the peritoneal cavity of pristane-treated BALB/c
mice (app. 5 × l06 hybridomas per mouse). mAbs were purified from clarified ascites by ammo-
nium sulfate precipitation and G protein chromatography. Class and subclass of mAbs were
determined by ELISA using a Bio-Rad isotyping kit. Antibody titers during immunization and
purification processes were determined by ELISA.
Characterization of mAbs
The specificity of mAbs was determined by immunoblotting using soluble crude extract from
the seven Leishmania species/strains as antigen (Table 1). The soluble crude antigens were
Table 1. Leishmania species used in this study.
Species WHO code Location of isolation Host Clinical form
L. donovani MHOM/CN/80/XJ801 China (Xinjiang) human VL
L. infantum MCAN/CN/90/SC China (Sichuan) dog VL
L. infantum MHOM/CN/08/JIASHI-1 China (Xinjiang) human VL
L. aethiopica MHOM/ET/72/L100 Ethiopia (Wollo) human CL
L. major MHOM/SU/75/5ASKH Turkmenistan human CL
L. tropica MHOM/SU/73/K27 Azerbaijan human CL
L. braziliensis MHOM/BR/75/M2903 Brazil (State of Pará) human CL
doi:10.1371/journal.pntd.0003902.t001
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separated by SDS-PAGE using a 10% polyacrylamide gel. Proteins were then electrophoreti-
cally transferred to nitrocellulose membranes which were blocked overnight with 5% skimmed
milk in PBS-T (PBS containing 0.05% Tween 20) at room temperature. The membranes were
washed once with PBS-T and then incubated overnight with the purified mAbs diluted 1:
20000 in PBS-T containing 5% skimmed milk at 4°C with constant shaking. Thereafter, mem-
branes were washed three times with PBS-T for 20 min and then incubated with goat anti-
mouse IgG secondary antibody conjugated to peroxidase diluted 1: 10000 in PBS containing
10% skimmed milk for 2 h at room temperature. The membranes were washed three times
with PBS-T, once with PBS and developed with 0.05% 3,3-diaminobenzidine and 0.015% H2O2
dissolved in PBS for 2 to 3 min. With the onset of color development, the reaction was stopped
by rinsing the membranes several times with double-distilled water.
Preparation and application of ICT
Colloidal gold was prepared using the sodium citrate reduction method and mAbs were conju-
gated with colloidal gold following the method described by Roe et al. [20]. The mAb A6A2 and
goat anti-mouse IgG antibody were sprayed onto nitrocellulose membranes in a 1-mm-wide
line (0.8 μg/cm) as test and control line, respectively. Detecting reagent (mAb E3C3-colloidal
gold conjugate) was incorporated into the sample pad. The test was carried out as follows: 10 μl
of serum or 20 μl of whole blood (in 15 U/ml of heparin) was applied to the sample pad of the
strip, then three drops of PBS were added, and the result was read after 15 min. The samples
were judged as positive once a pink color appeared in the test line regardless of its intensity.
Kalazar Detect Rapid Test assay
For comparison, the commercially available Kalazar Detect Rapid Test for visceral leishmania-
sis (InBios International, Inc., Seattle, USA) was used. This diagnostic tool is an ICT for the
detection of anti-L. donovani antibodies (anti-k39 antibody) in human serum and was carried
out according to the manufacturer’s instructions.
Data analysis
The definitions for sensitivity, specificity, true-positive values, false-positive values, true-nega-
tive values, false-negative values, and diagnostic efficiency were those as described by Gonzá-
lez-Sapienza et al. [21]. Sensitivity, specificity, true-positive values, false-positive values, true
negative values and false-negative values were calculated from a 2×2 table. Chi-squared test
was used for comparing the diagnostic parameters of the different tests. A p value of less than
0.05 was considered to be statistically significant. Kappa analysis was used to estimate the
degrees of agreement between the newly developed ICT and the Kalazar Detect Rapid Test. A κ
value of 0.81–1.00 indicates “almost perfect agreement”.
Results
Production of hybridomas and characterization of mAbs
After fusion of splenocytes isolated from a mouse immunized with soluble crude antigen of L.
donovaniMHOM/CN/80/XJ801 with cells of the murine myeloma line SP2/0, 12 hybridoma
lines secreting specific mAbs were obtained following three rounds of cloning. The mAbs
belonged to the IgG subclass IgG1 or IgG2a. When injecting the hybridomas in mice, the corre-
sponding antibody titers of ascites produced by the animals were between 1:25600 and
1:204800.
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Further tests indicated that two mAbs labelled A6A2 and E3C3 may recognize the same anti-
gen as determined by immunoblotting when using soluble crude antigen preparations from the
seven different Leishmania species/strains (Fig 1). The analysis showed that both mAbs recog-
nized an antigen of about 65 kDa from viscerotropic but not from dermotrophic Leishmania
species/strains. Additional analysis indicated that both mAbs recognized the same epitope of
the antigen (S1 Fig). Whether A6A2 and E3C3 are exactly the same mAbs remains to be deter-
mined. Nevertheless, the results suggested that the mAbs A6A2 and E3C3 may be suitable for
the development of an ICT for the diagnosis of VL.
Production of ICT strips
ICT strips to detect circulating Leishmania antigen were designed as a sandwich assay with
immobilized A6A2 mAb as the capturing antibody (test line) and colloidal gold labelled E3C3
mAb as the detecting reagent. Immobilized goat anti-mouse IgG antibody was incorporated to
confirm that the test operated correctly (control line). Fig 2 shows examples for the reactivity
of ICT strips with two different serum samples. With a negative serum sample, only the control
line developed (Fig 2A), while with a serum sample from a VL patient, both control and test
lines turned pink (Fig 2B). This finding showed that the developed ICT was able to detect cir-
culating Leishmania antigen in serum of VL patients.
Fig 1. Western blot analysis of mAbs A6A2 and E3C3. Soluble crude antigen preparations form different
Leishmania species/strains were analyzed by immunoblotting using mAbs A6A2 (A) and E3C3 (B). Lane M,
molecular marker; lane 1, L. donovaniMHOM/CN/80/XJ801; lane 2, L. infantumMCAN/CN/90/SC; lane 3, L.
infantumMHOM/CN/08/JIASHI-1; lane 4, L. aethiopicaMHOM/ET/72/L100; lane 5, L.majorMHOM/SU/75/
5ASKH; lane 6, L. tropicaMHOM/SU/73/K27; lane 7, L. braziliensisMHOM/BR/75/M2903.
doi:10.1371/journal.pntd.0003902.g001
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Evaluation of the ICT
The newly developed ICT was evaluated with 213 serum samples from VL patients. Of these,
95.8% (204) serum samples gave a positive reaction. With respect to the different endemic VL
areas, 98.4% (63 out of 64), 93.0% (66 out of 71) and 96.2% (75 out of 78) serum samples from
VL patients from AVL, DST-ZVL and MST-ZVL endemic regions showed a positive reaction,
respectively (Table 2). The serum samples were also tested with the commercially available
Kalazar Detect Rapid Test for VL, an ICT strip assay detecting antibodies of the L. donovani
Fig 2. Examples of ICT strips tested with serum samples from patients. (A) Results with a negative
serum sample: only the control line turned pink. (B) Results with a serum sample from a VL patient: both the
control and the test line turned pink.
doi:10.1371/journal.pntd.0003902.g002
Table 2. Number of positive serum samples from patients with VL and with other diseases, and from healthy individuals tested with the newly
developed ICT and the Kalazar Detect Rapid Test.
Serum samples No No of positive samples
Newly developed ICT Kalazar Detect
AVL 64 63 64
DST-ZVL 71 66 62
MST-ZVL 78 75 76
Leprosy 31 1 3
Malaria 43 1 1
Cystic echinococcosis 30 0 0
Schistosomiasis 25 0 0
Toxoplasmosis 27 1 1
Healthy donors 78 0 0
doi:10.1371/journal.pntd.0003902.t002
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complex in human serum. Of the 213 serum samples, 94.8% (202) tested positive with the Kala-
zar Detect Rapid Test. The individual results for VL patients from AVL, DST-ZVL and
MST-ZVL endemic areas were 100% (64 out of 64), 87.3% (62 out of 71) and 97.4% (76 out of
78), respectively (Table 2). Thus, the newly developed ICT detecting a circulating leishmanial
antigen performed as well as the commercially available Kalazar Detect Rapid Test detecting
an anti-leishmanial antibody.
Next, both ICTs were evaluated with 156 serum samples from patient with other diseases.
Only three and five serum samples gave a positive reaction with the newly developed ITC and
the Kalazar Detect Rapid Test, respectively (Table 2). The tests were also checked with 78
serum samples from healthy donors. All control samples were found to be negative by both
ICTs (Table 2).
In Table 3, the diagnostic parameters for the newly developed ICT and the Kalazar Detect
Rapid Test for the detection of VL are presented. For all the diagnostic parameters, not many
differences were found between the two ITCs. For both tests, sensitivity, specificity and diag-
nostic efficiency for the detection of VL were very similar being greater than 94% with similar
95% confidence intervals between 4–6 percentage points. Although statistical analysis revealed
no significant differences between the diagnostic parameters (p> 0.4, χ2< 0.5), the newly
developed ICT performed about 1 percentage point better than the Kalazar Detect Rapid Test
with respect to specificity, sensitivity and diagnostic efficiency. Apart from that, high degree
of agreement was observed between the new and the commercial test for the detection of VL
(κ = 0.986±0.008; 95% CI: 0.970 to 1.000).
Discussion
The diagnosis of VL presents many challenges because its clinical manifestations and symp-
toms are shared with other diseases such as malaria, disseminated tuberculosis, brucellosis,
enteric fever, schistosomiasis and hematological malignancies [22, 23]. However, early detec-
tion in humans and dogs (as the main animal reservoir) infected with Leishmania is imperative
if transmission of the disease is to be stopped in anthroponotic and zoonotic VL regions.
Therefore, rapid and accurate diagnosis is an essential component of VL management and con-
trol. As viscerotropic Leishmania species usually induce a strong humoral immune response,
serological tests detecting host antibodies offer a simple method for diagnosis of the disease.
These tests have generally good sensitivity [7] but are unable to distinguish between a current
and past infection due to the long persistence of parasite-specific antibodies in the body [8, 9].
Table 3. Diagnostic performance of the newly developed ICT and the Kalazar Detect Rapid Test in the
detection of VL.
Diagnostic parameter Newly developed ICT Kalazar Detect
True positive (tp) 204 202
True negative (tn) 231 229
False positive (fp) 3 5
False negative (fn) 9 11
Sensitivitya 95.8% (95% CI: 92.1–98.1%) 94.8% (95% CI: 91.0–97.4%)
Specificityb 98.7% (95% CI: 96.3–99.7%) 97.9% (95% CI: 95.1–99.3%)
Diagnostic efficiencyc 97.3% (95% CI: 95.4–98.6%) 96.4% (95% CI: 94.3–97.9%)
a Sensitivity = tp × 100/(tp + fn)
b Specificity = tn × 100/(tn + fp)
c Diagnostic efficiency = (tn + tp) × 100/(tp + fp + tn + fn)
doi:10.1371/journal.pntd.0003902.t003
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In addition, serological methods may present the problem of cross-reactivity with antibodies
from other infections (e.g. toxoplasmosis and malaria in the case of VL [24]) leading to false-
positive results.
The limitations of serological methods can be overcome by antigen detection tests. Since the
detection of Leishmania antigens would be indicative of the presence of the parasites in the
body, these tests may be useful for screening programs, therapy monitoring and cure confirma-
tion. A few antigen detection methods for the diagnosis of VL have been developed in recent
times. Using Western blot technique, De Colmenares et al. reported the detection of two poly-
peptide fractions of 72–75 kDa and 123 kDa in the urine of VL patients while the antigens were
not detectable in the urine of control individuals [25]. However, the test was only evaluated
with 15 urine samples from VL patients and its sensitivity varied between 67% (for the 123 kDa
fraction) and 93% (for the 72–75 kDa fraction). A heat-stable carbohydrate antigen detectable
in the urine of VL patients was described by Attar et al. [26, 27]. Based on this antigen, a latex
agglutination test was developed and when evaluated with urine samples from VL patients
from Brazil, Yemen and Nepal showed an overall sensitivity of 81.4% [26]. However, the sensi-
tivity of the test was disappointingly low (48–57%) in two field studies with confirmed VL
patients from an endemic kala-azar region in Nepal [28]. By contrast, our newly developed
ICT detecting a circulating antigen in blood or serum samples of VL patients performed much
better (95.8% sensitivity). This is probably due to the fact that our ICT is based on a sandwich
assay using two mAbs recognizing the same epitope that apparently occurs repeatedly on the
antigen. It seems that mAbs are better diagnostic reagents as they recognize a single epitope
with high specificity whereas polyclonal antibodies may be more sensitive but are often less
specific.
The performance of our antigen detecting ICT was better than most antibody detection
methods previously developed for diagnosis of VL. For example, various studies evaluating dif-
ferent immunological assays including ELISA, IFAT and DAT have shown that the sensitivities
and specificities of these tests vary between 55–100% and 72–100%, respectively [7]. The per-
formance of our ICT was also better than that of five other ICTs based on the rK39 antigen
(rK39 ICT) which showed an overall sensitivity of 91.9% and an overall specificity of 92.5%
[29]. The sensitivity of the rK39 ICT was lower in East Africa (85.3%) than in the Indian sub-
continent (97.0%) [29]. These differences in sensitivity may be due to differences in antibody
response in different ethnic groups and/or to differences in the K39 epitope in different strains
of Leishmania species of the L. donovani complex. Whether our ICT will also perform equally
well in other VL endemic regions outside of China remains to be shown.
Another advantage of our ICT over serological tests is that it is detecting a circulating para-
site antigen and thus should be able to distinguish between re-infection and relapse in the case
of recurrence, and should also be useful in diagnosing the disease in immunocompromised
patients (e.g. HIV patients co-infected with VL). The results obtained with serum samples
from VL patients from the DST-ZVL endemic area indicated that our ICT was indeed able to
detect the disease in patients with a weak immune system. Most patients of this region were
infants under one year old and thus at an age where their immune system is still underdevel-
oped producing only low antibody titers. Compared with the antibody detecting Kalazar Detect
Rapid Test, our ITC detected 5.6% more cases of VL in this cohort (Table 2).
In the absence of a practical gold standard (the best gold standard in VL diagnosis is the cul-
ture of parasites from splenic aspirates), diagnostic tests are needed that can rapidly and accu-
rately detect cases of VL under both field and laboratory conditions. The required performance
and operational characteristics of a diagnostic test for VL case detection are95% sensitivity,
98% specificity and30 min time to result [23]. With a sensitivity of 95.8% (95% CI: 92.1%
to 98.1%) and a specificity of 98.7% (95% CI: 96.3% to 99.7%), and with a development time of
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15 min, our ICT fulfils these requirements. However, before our ICT can be recommended for
clinical use, it needs to be validated in large-scale prospective studies outside of China in order
to confirm its performance (sensitivity, specificity and reproducibility) and operational charac-
teristics (user-friendliness and stability) in other VL endemic regions such as East Africa and
South America.
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